Management of proctitis in ulcerative colitis and the place of biological therapies.

IF 3.6 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Expert Opinion on Biological Therapy Pub Date : 2024-06-01 Epub Date: 2024-06-17 DOI:10.1080/14712598.2024.2369189

Diletta De Deo, Arianna Dal Buono, Roberto Gabbiadini, Paola Spaggiari, Anita Busacca, Benedetta Masoni, Silvia Ferretti, Cristina Bezzio, Alessandro Armuzzi

{"title":"Management of proctitis in ulcerative colitis and the place of biological therapies.","authors":"Diletta De Deo, Arianna Dal Buono, Roberto Gabbiadini, Paola Spaggiari, Anita Busacca, Benedetta Masoni, Silvia Ferretti, Cristina Bezzio, Alessandro Armuzzi","doi":"10.1080/14712598.2024.2369189","DOIUrl":null,"url":null,"abstract":"Introduction: Approximately 20-30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms.Areas covered: PubMed was searched up to March 2024 to identify relevant studies on UP. A comprehensive summary and critical appraisal of the available data on UP are provided, highlighting emerging treatments and areas for future research.Expert opinion: Patients with UP are often undertreated, and the disease burden is often underestimated in clinical practice. Treat-to-target management algorithms can be applied to UP, aiming for clinical remission in the short term, and endoscopic remission and maintenance of remission in the long term. During their disease, approximately one-third of UP patients require advanced therapies. Escalation to biologic therapy is required for refractory or steroid dependent UP. For optimal patient care and management of UP, it is necessary to include these patients in future randomized clinical trials.","PeriodicalId":12084,"journal":{"name":"Expert Opinion on Biological Therapy","volume":" ","pages":"443-453"},"PeriodicalIF":3.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Biological Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14712598.2024.2369189","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Approximately 20-30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms.

Areas covered: PubMed was searched up to March 2024 to identify relevant studies on UP. A comprehensive summary and critical appraisal of the available data on UP are provided, highlighting emerging treatments and areas for future research.

Expert opinion: Patients with UP are often undertreated, and the disease burden is often underestimated in clinical practice. Treat-to-target management algorithms can be applied to UP, aiming for clinical remission in the short term, and endoscopic remission and maintenance of remission in the long term. During their disease, approximately one-third of UP patients require advanced therapies. Escalation to biologic therapy is required for refractory or steroid dependent UP. For optimal patient care and management of UP, it is necessary to include these patients in future randomized clinical trials.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

溃疡性结肠炎直肠炎的治疗与生物疗法的地位。

简介：约 20-30% 的溃疡性结肠炎（UC）患者可能会出现孤立性直肠炎。溃疡性直肠炎（UP）是一种具有挑战性的疾病，因为它给患者带来了严重的致残症状：对截至 2024 年 3 月的 PubMed 进行了检索，以确定有关溃疡性直肠炎的相关研究。本文对现有的UP数据进行了全面总结和批判性评估，强调了新出现的治疗方法和未来的研究领域：专家意见：UP 患者往往得不到充分治疗，在临床实践中疾病负担往往被低估。治疗目标管理算法可用于UP，目的是在短期内实现临床缓解，在长期内实现内镜缓解并维持缓解。在患病期间，约有三分之一的 UP 患者需要接受晚期治疗。难治性或类固醇依赖性UP患者需要升级到生物疗法。为了优化患者护理和UP管理，有必要将这些患者纳入未来的随机临床试验中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Biological Therapy 医学-生物工程与应用微生物

CiteScore

8.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease. The journal welcomes: Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine Drug evaluations reviewing the clinical data on a particular biological agent Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points.